Marcel Van Gaalen

Leadership of the Charles River site that is specialized in preclinical research supporting the development of innovative therapies in a broad range of human diseases, in particular psychiatric and neurological disorders. Performance of pharmacodynamics and pharmacokinetic studies with focus on translational value. Specialist in intrathecal and intracerebral drug administration and sampling for PK/PD relationship.

Encepharm is a specialist preclinical research organization supporting the development of innovative therapies in a broad range of human diseases in particular psychiatric and neurological disorders. We provide preclinical research services using our long-term expertise as well as cutting edge research in collaboration with our academic partners. We perform pharmacodynamics and pharmacokinetic studies with focus on translational value.

Encepharm is a specialist preclinical research organization supporting the development of innovative therapies in a broad range of human diseases in particular psychiatric and neurological disorders. We provide preclinical research services using our long-term expertise as well as cutting edge research in collaboration with our academic partners. We perform pharmacodynamics and pharmacokinetic studies with focus on translational value.

Group leader of behavioral pharmacology for neuroscience, which support target validation and lead optimization for indication including Alzheimer’s disease, schizophrenia, depression and cognitive disorders. Responsible for the setup, evaluation and use of behavioral models of neurological and psychiatric disorders. Extended experience and understanding of related disciplines such as PK/PD relation, endocrinology and translational approaches.

Group leader of behavioral pharmacology for neuroscience, which support target validation and lead optimization for indication including Alzheimer’s disease, schizophrenia, depression and cognitive disorders. Responsible for the setup, evaluation and use of behavioral models of neurological and psychiatric disorders. Extended experience and understanding of related disciplines such as PK/PD relation, endocrinology and translational approaches.

Group leader of behavioral pharmacology for neuroscience, which support target validation and lead optimization for indication including Alzheimer’s disease, schizophrenia, depression and cognitive disorders. Responsible for the setup, evaluation and use of behavioral models of neurological and psychiatric disorders. Extended experience and understanding of related disciplines such as PK/PD relation, endocrinology and translational approaches.

• Main topic: long-term effects of drugs of abuse on cognitive functions. • Establishment of a preclinical cognition laboratory. • Strong contribution of the understanding of the differences in constructs of impulsivity in the international literature. • Expertise in drug abuse research field. • Supervision of technical assistants and students.

• Onset of action of antidepressants. • In vivo electrophysiological approach in rats and guinea pigs, iontophoretic application and stimulation of neurons.

Neuroscience, psychiatry, cognition, depression, anxiety

In vivo pharmacology